RxDoctor Payments Data

Michael Henderson, MD

Cardiovascular Disease · Georgetown, TXNPI 1518166354

Payments from drug & device makers

$1,813in general payments, 2019–2025

Across 106 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$441
  • Novartis$308
  • Johnson & Johnson$252
  • Merck$171
  • Boston Scientific$110
  • Abbott$104
  • plus $426 from 11 others

What the payments were for

  • Food & beverage$1,813100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,813 in reported general payments places this provider in the 30th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$278,769
Medicare patients
1,239
Services billed
3,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban251$283,349
EntrestoSacubitril/Valsartan189$260,128
XareltoRivaroxaban244$242,165
Repatha SureclickEvolocumab139$94,102
MultaqDronedarone Hcl24$26,884
VascepaIcosapent Ethyl23$19,627
Praluent PenAlirocumab30$15,944
BrilintaTicagrelor14$9,836
Metoprolol Succinate398$4,906
Prasugrel Hcl52$4,348
Losartan Potassium366$4,234
Atorvastatin Calcium420$4,170
Flecainide Acetate106$4,051
Rosuvastatin Calcium230$3,930
Nebivolol Hcl27$2,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$283,349251 claims
NovartisEntresto$308$260,128189 claims
Johnson & JohnsonXarelto$252$242,165244 claims
Sanofi-aventis U.S. LLCMultaq$43$26,88424 claims
AstraZenecaBrilinta$31$9,83614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Georgetown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →